Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated as 25% of aprocitentan is cleared through the liver. Aprocitentan is in clinical development for the treatment of resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontes, Magda S. C., Dingemanse, Jasper, Halabi, Atef, Tomaszewska-Kiecana, Monika, Sidharta, Patricia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645340/
https://www.ncbi.nlm.nih.gov/pubmed/36352054
http://dx.doi.org/10.1038/s41598-022-22470-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645340/
https://www.ncbi.nlm.nih.gov/pubmed/36352054
http://dx.doi.org/10.1038/s41598-022-22470-z

Ejemplares similares